Sunniva Inc is vertically integrated medical cannabis company committed to delivering safe, low-cost, high-quality products and services at scale. The company is focused on the cultivation, production and distribution of therapeutic solutions targeting two of the medical cannabis markets in the world: Canada and California.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1856
No trial phase data available
No trial data available
No trial data available
No approval data available
- MediWound reported second-quarter 2026 revenue of $3.1 million, down 45.6% year over year, primarily reflecting the timing of BARDA-funded development revenue. - The EscharEx Phase III VALU trial in venous leg ulcers remains on track, with interim sample-size reassessment and enrollment completion expected by the end of Q1 2027. - An updated independent U.S. market assessment, expanded to include pressure ulcers, now projects $1.05 billion in annual peak sales for EscharEx. - Vericel reported NexoBrid's strongest quarter since launch, with approximately 80 U.S. burn centers ordering the product, and MediWound reaffirmed full-year 2026 revenue guidance of $24 million to $26 million.
- TG-C, a first-in-class cell and gene therapy for knee osteoarthritis, failed to demonstrate statistically significant improvements over placebo in VAS pain and WOMAC function scores at 12 months in the ACTiVION-II Phase 3 trial. - The study enrolled 531 patients across 27 U.S. sites; both TG-C and placebo groups showed similar improvements from baseline, with a higher-than-expected placebo response potentially influencing results. - No new safety concerns emerged, and the rate of total knee replacement was lower in the TG-C group (0.6%) compared to placebo (5.3%). - Results from ACTiVION-I, the second independent Phase 3 trial conducted under the same protocol, are anticipated in October 2026.
- Elutia Inc. has appointed Pete Ligotti as Chief Commercial Officer to lead the commercialization of NXT-41x, a next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. - NXT-41x targets the breast reconstruction market where over 162,000 procedures are performed annually in the U.S., yet infection rates of 15% to 20% persist despite biological surgical mesh being standard in over 80% of cases. - The biologics for breast reconstruction market represents an estimated $1.5 billion total U.S. market opportunity, with Elutia anticipating FDA clearance for NXT-41x in 2027. - Ligotti brings twenty years of commercial execution experience in complex surgical markets, including building Integra LifeSciences' plastic and reconstructive surgery operation and scaling specialty surgical businesses to over $180 million in revenue.
